An observational study in Sleep Apnoea, sponsored by Imperial College London Diabetes Centre. Status unknown at 1 site in United Arab Emirates. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Imperial College London Diabetes Centre · Observational
Obstructive sleep apnoea (OSA) is a common medical problem which, despite increasing awareness, remains under-diagnosed. There is a close association between OSA and obesity; 60-70% of patients diagnosed with OSA are either obese or overweight [1]. OSA is also very common among patients with type 2 diabetes. Type 2 Diabetes Mellitus (T2DM) has reached epidemic status in the Gulf region. OSA worsens insulin resistance and leads to weight gain through sleep disturbance [2]. Several mechanisms have been proposed for the associations of OSA with diabetes and obesity [3]. At present there is little available information regarding the prevalence of OSA in the UAE, the relationship with T2DM and obesity, and the impact of OSA on health outcomes in the Emirati population. This research will explore these relationships and inform public health decisions regarding diagnostic pathways, service provision and treatment protocols.
1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.
This study's planned enrollment of 1,400 is above the median of 106 across 386 observational studies indexed under Apnea.
Browse Apnea studies →Imperial College London Diabetes Centre is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients over the age of 18 attending ICLDC will be offered the option of taking part in the study. Those agreeing to participate will be asked to fill in a questionnaire.
Participants aged between 18-64 years old. Both Gender male and female.
Exclusion Criteria:
Paediatrics below the age of 18. Any participant who is unable to take part
Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
Other: Questionnaire
Patients with blood glucose between 5.6mmol/L - 7mmol/L
Other: Questionnaire
Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
Other: Questionnaire
Patients on insulin and with positive IA2 and/or GAD antibodies.
Other: Questionnaire
Primary objective (Establishing the prevalence of OSA in the study population.)
Establishing the prevalence of OSA in the study population.
Time frame: 3 months
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College London Diabetes Centre